Pharming Group (NASDAQ:PHAR) Shares Down 8.8%

Pharming Group (NASDAQ:PHAR) shares fell 8.8% during mid-day trading on Friday . The stock traded as low as $9.53 and last traded at $9.53. 1,241 shares traded hands during trading, a decline of 52% from the average session volume of 2,603 shares. The stock had previously closed at $10.45.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 14th.

Pharming Group Stock Down 6.2 %

The company has a debt-to-equity ratio of 0.62, a current ratio of 4.06 and a quick ratio of 3.33. The firm has a market cap of $657.67 million, a price-to-earnings ratio of -70.00 and a beta of 0.16. The firm has a 50 day moving average price of $10.83 and a 200-day moving average price of $11.42.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.08). Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. The company had revenue of $81.20 million during the quarter, compared to analyst estimates of $71.83 million. As a group, equities analysts predict that Pharming Group will post -0.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC bought a new stake in Pharming Group (NASDAQ:PHAR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 17,710 shares of the company’s stock, valued at approximately $202,000. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.